Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Valion Bio, Inc.VBIO · Entity 8459 | Director · Interim CEO | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Valion Bio, Inc.
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 50,000 |
Reported balance
After 2026-09-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-22 · Grant · Acquired 50,000 · Balance 50,000 F1: Each Restricted Stock Unit is convertible into one share of Common Stock. F2: One fourth (1/4) of the Restricted Stock Units shall vest quarterly, with the first vesting occurring on December 22, 2026. F3: These numbers have been adjusted to reflect the reverse stock split of the common stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit is convertible into one share of Common Stock.
F2: One fourth (1/4) of the Restricted Stock Units shall vest quarterly, with the first vesting occurring on December 22, 2026.
F3: These numbers have been adjusted to reflect the reverse stock split of the common stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 24, 2026 20:46 UTC | Valion Bio, Inc. VBIO · Entity 8459 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-007398 · ownership.xml · derivative · entry 1 Zikria Dean · CIK 0001877611 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit is convertible into one share of Common Stock. F2 · derivative.exercise_date: One fourth (1/4) of the Restricted Stock Units shall vest quarterly, with the first vesting occurring on December 22, 2026. F2 · derivative.expiration_date: One fourth (1/4) of the Restricted Stock Units shall vest quarterly, with the first vesting occurring on December 22, 2026. F3 · balance_after: These numbers have been adjusted to reflect the reverse stock split of the common stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 18:46 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantStock Option (Right to Purchase) · Derivative | 7,500 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001683168-25-005837 · ownership.xml · derivative · entry 1 Zikria Dean · CIK 0001877611 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2035-08-05 F1 · derivative.exercise_date: The stock option vests in a series of four (4) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the grant date, such that 100% of the stock option will be vested upon the first anniversary of the grant date. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 17:15 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantStock Option (Right to Purchase) · Derivative | 12,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001683168-24-008902 · ownership.xml · derivative · entry 1 Zikria Dean · CIK 0001877611 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2034-12-17 F1 · derivative.exercise_date: The Option Shares will vest and become exercisable in a series of twelve (12) successive equal monthly installments, rounded downward to the nearest whole share, measured from the Vesting Commencement Date, such that 100% of the Option Shares will be vested and exercisable upon the first (1st) anniversary of the Vesting Commencement Date. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 17:48 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0000950170-24-096479 · ownership.xml · derivative · entry 1 Zikria Dean · CIK 0001877611 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2034-08-08 F1 · derivative.exercise_date: The option vests in a series of twelve (12) successive equal monthly installments, rounded downward to the nearest whole share, from the grant date, such that 100% of the option will be vested upon the first anniversary of the grant date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 17:30 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0000899243-23-015785 · doc4.xml · derivative · entry 1 Zikria Dean · CIK 0001877611 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: The option vests as follows: (i) 50% on the first anniversary of the grant date, (ii) 25% on the second anniversary of the grant date, and (iii) 25% on the third anniversary of the grant date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 19:44 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001104659-22-072042 · tm2218712-1_4seq1.xml · derivative · entry 1 Zikria Dean · CIK 0001877611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-13 F1 · derivative.exercise_date: The option vests as follows: (i) 50% one year from the grant date, and (ii) the remaining 50% in equal monthly installments over the next 24 months. Read SEC document |
| June 14, 2022 Filed Jun 21, 2022 17:23 UTC Amendment | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001104659-22-073070 · tm2218957-1_4aseq1.xml · derivative · entry 1 Zikria Dean · CIK 0001877611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-13 F1 · derivative.exercise_date: This Amendment No. 1 ("Form 4/A") to the Form 4 filed by the reporting person on June 16, 2022 (the "Original Form 4") is being filed to correct an administrative error, resulting in the incorrect versting schedule being included for the option. As reflected in this Form 4/A, the option vests as follows: (i) 50% on the first anniversary of the grant date, (ii) 25% on the second anniversary of the grant date, and (iii) 25% on the third anniversary of the grant date. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 20:38 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-21-150713 · tm2135733d3_4.xml · derivative · entry 1 Zikria Dean · CIK 0001877611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-12-13 F1 · derivative.exercise_date: The option will vest one year from the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.